4.5 Review

Targeting Notch signaling in pancreatic cancer

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 14, Issue 5, Pages 541-552

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/14728221003769895

Keywords

cancer; notch; pancreas; signalling

Funding

  1. Institut National de la Sante et de la Recherche Medicale (INSERM) (Paris, France)
  2. Universitede la Mediterranee (Marseille, France)

Ask authors/readers for more resources

Areas covered in this review: Our aim is to present the Notch pathway, and to describe its involvement in pancreatic pathophysiology/carcinogenesis. This pathway appeared as a prime target for pancreatic cancer therapy. In the light of the crosstalk of Notch with other survival/embryologic pathways, drugs affecting more than one pathway may have to be combined. What the reader will gain: Drugs against gamma-secretases could thus serve in cancer treatment and can be combined with drugs targeting survival pathways interplaying with Notch such as Hedgehog. Take home message: Downregulation of Notch contributes to the inhibition and apoptosis of pancreatic cancer cells whereas Hedgehog inhibition will allow for enhanced delivery of drugs to the tumor. Both pathway inhibitors appear to have synergistic effects for future therapeutics for pancreatic adenocarcinoma, once safety issues of compounds are overcome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available